Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $114.57 USD
Change Today -0.71 / -0.62%
Volume 10.6M
CELG On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 5:20 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CELG) Snapshot

Open
$114.88
Previous Close
$115.28
Day High
$115.65
Day Low
$111.70
52 Week High
03/20/15 - $129.06
52 Week Low
04/15/14 - $66.85
Market Cap
91.7B
Average Volume 10 Days
7.9M
EPS TTM
$2.56
Shares Outstanding
800.6M
EX-Date
--
P/E TM
44.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CELG)

celgene corp (CELG) Related Businessweek News

View More BusinessWeek News

celgene corp (CELG) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CELG) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.3M
President and Chief Operating Officer
Total Annual Compensation: $666.7K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $645.8K
President of Global Hematology and Oncology
Total Annual Compensation: $753.3K
President of Research & Early Development an...
Total Annual Compensation: $645.8K
Compensation as of Fiscal Year 2013.

celgene corp (CELG) Key Developments

Celgene Corporation(NasdaqGS:CELG) added to S&P 100 Index

Celgene Corporation(NasdaqGS:CELG) added to S&P 100 Index

Celgene Corporation Announces Results from its Ongoing Phase III LIBERATE Trial Evaluating Otezla

Celgene Corporation announced results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate to severe plaque psoriasis were presented at a late-breaker presentation at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco, California. The LIBERATE study evaluated the clinical efficacy and safety of either oral OTEZLA 30 mg twice daily or weekly subcutaneous (SC) etanercept 50 mg compared with placebo at week 16 in 250 patients who had no prior exposure to a biological therapy. It also examined the relative safety of a switch from etanercept to OTEZLA after week 16. At week 16, patients receiving OTEZLA 30 mg twice daily demonstrated statistically significant and clinically meaningful improvement when compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) -75 response [primary endpoint; 40% with OTEZLA (n=33/83), 12% with placebo (n=10/84), PAbout LIBERATE™ LIBERATE (PSOR-010; EvaLuatIon from a PlaceBo-controllEd Study of ORal ApremilasT and Etanercept in Plaque Psoriasis) is a phase IIIb, multicenter, randomized, placebo-controlled, double-blind, double-dummy study of the efficacy and safety of OTEZLA, etanercept and placebo, in subjects with moderate to severe plaque psoriasis. The primary objective of the LIBERATE study was to evaluate the clinical efficacy and safety of oral OTEZLA 30 mg twice daily compared with placebo at week 16. Secondary objectives of the study included: the evaluation of the clinical efficacy and safety of etanercept 50 mg SC once weekly (QW) compared with placebo at week 16 and the evaluation of the relative safety of a crossover from etanercept to OTEZLA 30 mg twice daily, as compared with OTEZLA dosed since week 0, after week 16. Subjects were required to have inadequate response, intolerance or contraindication to at least one conventional systemic agent and no prior exposure to biologics. The study enrolled 250 subjects who were randomized 1:1:1 to receive OTEZLA 30 mg twice daily, etanercept 50 mg QW or placebo, for 16 weeks. Following the first 16 weeks, all subjects were switched to (or continued on) OTEZLA 30 mg twice daily through week 104. The primary endpoint was the proportion of subjects with either OTEZLA 30 mg twice daily or placebo who achieved PASI-75 at week 16. Secondary endpoints included other measures of disease activity and quality of life for the comparison of OTEZLA 30 mg twice daily versus placebo and the comparison of etanercept 50 mg SC QW versus placebo.

Celgene Corporation Announces Results from Long-Term Efficacy and Safety Analyses of the Esteem Phase III Clinical Trial Program of Otezla

Celgene Corporation announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast). OTEZLA is the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4) approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for the treatment of adults with active psoriatic arthritis. In ESTEEM 1 and 2, patients were randomized to treatment with OTEZLA 30 mg twice daily or placebo for the first 16 weeks. At week 16, patients either continued on OTEZLA or were switched from placebo to OTEZLA 30 mg twice daily through week 32. Patients initially randomized to OTEZLA who achieved a Psoriasis Area and Severity Index (PASI)-75 response (ESTEEM 1) or PASI-50 response (ESTEEM 2) at week 32 were then re-randomized to either OTEZLA 30 mg twice daily or placebo. An analysis of data from ESTEEM 2 presented at AAD showed sustained improvements at week 52 among PASI-50 responders (patients who achieved a 50% reduction in PASI at week 32) in difficult-to-treat areas such as nails, scalp and the palms of the hands and soles of the feet (known as palmoplantar psoriasis). Among patients who had nail psoriasis at baseline with a Nail Psoriasis Severity Index (NAPSI) greater than or equal to one, 45% (78/175) of those treated with OTEZLA 30 mg twice daily had at least a 50% improvement in NAPSI (NAPSI-50) at week 16, compared with 19% (17/91) of those treated with placebo (P<0.0001). NAPSI-50 achievement was generally maintained for up to 52 weeks in patients (69%, n=35) who received OTEZLA at baseline who were PASI-50 responders. Of those patients who had moderate to very severe scalp psoriasis at baseline, 41% (72/176) of those treated with OTEZLA 30 mg twice daily had a Scalp Physician Global Assessment (ScPGA) score of clear (zero) or minimal (one) at week 16, compared with 17% (16/93) of those treated with placebo (P<0.0001). ScPGA score of zero or one achievement was generally maintained for up to 52 weeks in patients (63%, n=32) who received OTEZLA at baseline who were PASI-50 responders. Among patients who had moderate to severe psoriasis on their palms and feet at baseline, 65% (17/26) of those treated with OTEZLA 30 mg twice daily had a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of clear (zero) or almost clear (one) at week 16, compared with 31% (5/16) of those treated with placebo (P=0.0315). PPPGA score of zero or one achievement was sustained up to week 52 (n=4 of 4 patients) in patients randomized to OTEZLA who were PASI-50 responders at week 32. An analysis of PSOR-005, ESTEEM 1 and ESTEEM 2 found that OTEZLA improved palmoplantar psoriasis in a subset of patients with moderate to severe chronic plaque psoriasis who had palmoplantar involvement. Of those patients who had any palmoplantar psoriasis at baseline (PPPGA score of one or greater, n=427 across the three studies " 49 in PSOR-005, 254 in ESTEEM 1 and 124 in ESTEEM 2), a percent of patients treated with OTEZLA 30 mg twice daily had PPPGA reduced to clear or almost clear compared with placebo at week 16 in all three trials [PSOR-005: 70% (19/27) vs. 32% (7/22), respectively, P=0.0072; ESTEEM 1: 63% (107/169) vs. 45% (38/85), respectively, P=0.0047; ESTEEM 2: 71% (55/78) vs. 37% (17/46), respectively, P=0.0003]. Among patients who had moderate to severe palmoplantar psoriasis at baseline (PPPGA score of three or greater) (n=144 across the three studies " 19 in PSOR-005, 83 in ESTEEM 1 and 42 in ESTEEM 2), a percentage of patients treated with OTEZLA 30 mg twice daily had PPPGA reduced to clear or almost clear compared with placebo at week 16 in PSOR-005 [67% (6/9) vs. 20% (2/10), respectively, P=0.0397] and ESTEEM 2 [65% (17/26) vs. 31% (5/16), respectively, P=0.0315]. There was no significant difference between the OTEZLA and placebo groups at week 16 in ESTEEM 1 [39% (22/57) vs. 31% (8/26), respectively, P=0.4912]. Long-term (104-week) results from the ESTEEM 1 trial showed that no new safety signals were identified in patients treated with OTEZLA 30 mg twice daily for up to two years (844 patients were randomized, 444 continued in the second year). As with adverse events (AEs) reported during the first 52 weeks of exposure, most AEs reported during weeks 52 to 104 were mild or moderate in severity and did not lead to discontinuation. The most frequently reported AEs during the placebo-controlled period and the OTEZLA-exposure periods were diarrhea, upper respiratory tract infection, nausea, nasopharyngitis, tension headache and headache. The exposure adjusted incidence rate (EAIR) for serious AEs did not increase with longer OTEZLA exposure, compared with the placebo-controlled period. There were no clinically meaningful changes in laboratory measurements identified over the OTEZLA 104-week exposure period. Incidence rates of major cardiac events, solid tumors, hematological malignancies and serious infections were comparable between the placebo and OTEZLA arms during the placebo-controlled period. No increase in incidence rates was noted with longer-term exposure to OTEZLA between weeks 52 to 104.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $114.57 USD -0.71

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.10 USD -1.44
Biogen Inc $413.81 USD -8.43
Bristol-Myers Squibb Co $63.56 USD -0.94
Eli Lilly & Co $71.53 USD -1.12
Shire PLC 5,260 GBp -105.00
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 50.2x
Price/Sales 12.5x
Price/Book 14.7x
Price/Cash Flow 42.6x
TEV/Sales 10.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.